Marc Machaalani
Hospital ResidentCards
About
Research
Publications
2026
The clinical landscape of HIF2α inhibitors in oncology
Saad E, Machaalani M, McDermott D, Choueiri T. The clinical landscape of HIF2α inhibitors in oncology. Nature Reviews Clinical Oncology 2026, 23: 501-519. PMID: 42050152, DOI: 10.1038/s41571-026-01145-y.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsPublisher Correction: argeting of HIF2-driven cachexia in kidney cancer
Abu-Remaileh M, Stransky L, Bhalerao N, Shirole N, Jiang Q, Saad E, Machaalani M, Vigeant S, Woldemichael H, Xu C, Lu J, Wei H, Liu Z, Sun W, Enomoto K, Choueiri T, Pitarresi J, Carr S, Udeshi N, Kaelin W. Publisher Correction: argeting of HIF2-driven cachexia in kidney cancer. Nature Medicine 2026, 32: 766-766. PMID: 41606123, PMCID: PMC12920078, DOI: 10.1038/s41591-026-04236-6.Commentaries, Editorials and LettersIntegrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2
Yekedüz E, Bian W, Siegmund S, Machaalani M, Masri J, Saleh M, Saad E, Ascione L, Chehade R, Steiner C, Barrios P, Berg S, McGregor B, Mantia C, Ravi P, Xu W, Hirsch M, Choueiri T, Serzan M. Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2. Clinical Cancer Research 2026, 32: 1169-1179. PMID: 41524698, PMCID: PMC12924687, DOI: 10.1158/1078-0432.ccr-25-2871.Peer-Reviewed Original ResearchSoluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma
Alves Costa Silva C, Machaalani M, Saliby R, Zhong C, Xie W, Pasolli E, Piccinno G, Dalban C, Fidelle M, Meurisse A, Vernerey D, Lee G, Birebent R, Saad E, Steiner C, Flippot R, Barros-Monteiro J, Segata N, Thiery-Vuillemin A, Formenti S, Kuznetsova T, Escudier B, Derosa L, Zitvogel L, Choueiri T, Albiges L. Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma. Nature Medicine 2026, 32: 671-681. PMID: 41501493, PMCID: PMC12920104, DOI: 10.1038/s41591-025-04067-x.Peer-Reviewed Original ResearchChapter 4 Stem cell-mediated alleviation of pyroptosis in cerebral injuries
Masri J, Masri D, Saleh M, Al Chaar S, Machaalani M, Bahmad H, Abou-Kheir W. Chapter 4 Stem cell-mediated alleviation of pyroptosis in cerebral injuries. 2026, 111-130. DOI: 10.1016/b978-0-443-40471-9.00004-5.Chapters
2025
Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer
Nassar A, Farhat E, Abushukair H, Alchoueriy M, Salem S, Machaalani M, Adib E, Henske E, Babu P, Choueiri T, Rakaee M, Busund L, Takabe Y, Lau S, Rall K, Naqash A, Jansen C, Wang X, Challa P, Tarantino P, Partridge A, Tolaney S, Kwiatkowski D, Winer E. Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer. Journal Of The National Cancer Institute 2025, 118: 669-679. PMID: 41418409, DOI: 10.1093/jnci/djaf344.Peer-Reviewed Original ResearchTargeting of HIF2-driven cachexia in kidney cancer
Abu-Remaileh M, Stransky L, Bhalerao N, Shirole N, Jiang Q, Saad E, Machaalani M, Vigeant S, Woldemichael H, Xu C, Lu J, Wei H, Liu Z, Sun W, Enomoto K, Choueiri T, Pitarresi J, Carr S, Udeshi N, Kaelin W. Targeting of HIF2-driven cachexia in kidney cancer. Nature Medicine 2025, 32: 245-257. PMID: 41315757, PMCID: PMC12823431, DOI: 10.1038/s41591-025-04054-2.Peer-Reviewed Original ResearchThe SLC1A1/EAAT3 dicarboxylic amino acid transporter is an epigenetically dysregulated nutrient carrier that sustains oncogenic metabolic programs
Grubb T, Koochaki P, Matar S, Ghandour F, Machaalani M, Saad E, Tang C, Reznik E, Khatun J, Salem C, Dubasik N, Orlando D, Guenther M, Parajuli G, Srivastava R, Martinez S, Coker J, Kotecha R, Hakimi A, Asara J, Chan T, Vanharanta S, Stauffer S, Kaelin W, Signoretti S, Choueiri T, Chakraborty A. The SLC1A1/EAAT3 dicarboxylic amino acid transporter is an epigenetically dysregulated nutrient carrier that sustains oncogenic metabolic programs. Nature Communications 2025, 16: 10012. PMID: 41238532, PMCID: PMC12618888, DOI: 10.1038/s41467-025-64983-x.Peer-Reviewed Original ResearchMLH1 Mismatch Repair Deficiency Predicts Exceptional Response to Immune Checkpoint Inhibition in Clear-cell Renal Cell Carcinoma
Dawidek M, Calderon L, Shah P, Mittal R, Ucpinar B, Bakouny Z, Meli K, Saad E, Saliby R, Woo H, Khandwala Y, Eid M, Labaki C, Machaalani M, Coleman J, Russo P, Kotecha R, Carlo M, Akin O, Braun D, Choueiri T, Reznik E, Chen Y, Motzer R, Voss M, Hakimi A. MLH1 Mismatch Repair Deficiency Predicts Exceptional Response to Immune Checkpoint Inhibition in Clear-cell Renal Cell Carcinoma. European Urology 2025 PMID: 41193371, DOI: 10.1016/j.eururo.2025.09.4162.Peer-Reviewed Original Research39Intratumoral viral transcriptomic signatures stratify immune phenotypes and clinical outcomes in renal cell carcinoma (RCC)
Saleh M, Saad E, Barrios P, Machaalani M, Ascione L, Khatoun W, Masri J, Chehade R, Eid M, Nawfal R, Semaan K, Yekeduz E, Steiner C, Bian W, Sun M, Signoretti S, Van Allen E, Braun D, Gusev A, Choueri T. 39Intratumoral viral transcriptomic signatures stratify immune phenotypes and clinical outcomes in renal cell carcinoma (RCC). The Oncologist 2025, 30: oyaf276.040. PMCID: PMC12509656, DOI: 10.1093/oncolo/oyaf276.040.Peer-Reviewed Original Research